Evidence map›Paper›PMID 40619808›Full record

ArticleImmunotherapy2025

Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.

Siqi Qiu, Zhipeng Zong, Kang He

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Siqi QiuDepartment of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhipeng ZongDepartment of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Kang HeDepartment of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-4671-1337

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of immune checkpoint inhibitors (ICIs) on transplant rejection remains controversial. We report a case of a hepatocellular carcinoma patient who received Atezolizumab plus Bevacizumab regimen prior to liver transplantation and developed steroid-refractory T cell-mediated rejection combined with antibody-mediated rejection post-transplant. Given the short discontinuation and outstanding tumor response, we believe that the use of ICIs prior to transplantation contributed to this complex condition. The rejection was successfully cured with anti-thymocyte globulin (ATG) combined with an anti-CD20 monoclonal antibody (Rituximab). After 9-months follow-up, no tumor recurrence occurs. This case highlights the unique immune activation state affecting both T and B lymphocytes induced by ICIs. It also provides a case reference for the use of intensive immunosuppressive regimens in ICI recipients experiencing adverse reactions.

Indexed as

B-LymphocytesCarcinoma, HepatocellularGraft RejectionImmune Checkpoint InhibitorsLiver NeoplasmsLiver TransplantationAntibodies, Monoclonal, HumanizedAntilymphocyte SerumBevacizumabHumansImmunosuppressive AgentsLymphocyte DepletionMaleMiddle AgedRituximabT-LymphocytesAntibodies, Monoclonal, HumanizedAntilymphocyte SerumatezolizumabBevacizumabImmune Checkpoint InhibitorsImmunosuppressive AgentsRituximabanti-thymocyte globulinImmune checkpoint inhibitorsliver transplantRituximabsteroid-refractory rejection

Identifiers

PMID40619808
PMCPMC12355717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.